Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases

Research output: Contribution to journalArticle

Abstract

Aim: To study clinical outcome for oligometastatic patients (abdominal lymph-node metastases) treated with stereotactic body radiation therapy. Materials and methods: Seventy-one patients were studied retrospectively. Dose prescription was 45 Gy in six fractions. Clinical outcome was assessed with actuarial analysis. Results: The median follow-up was 1.5 years; 45 patients (63.3%) had solitary metastasis, and 26 (36.6%) had multiple lesions. Local control was achieved in 97.5% with a 1-year actuarial rate of 83%. Two-year progression-free survival was 63.1%, and the overall survival was 76.9%. Two patients (3%) developed grade 2 gastro-enteric toxicity. Conclusions: The treatment provided adequate clinical response in the management of oligometastatic cases.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalCancer Investigation
DOIs
Publication statusAccepted/In press - Jun 24 2016

Fingerprint

Photons
Radiotherapy
Lymph Nodes
Neoplasm Metastasis
Actuarial Analysis
Case Management
Therapeutics
Disease-Free Survival
Prescriptions
Outcome Assessment (Health Care)
Survival

Keywords

  • Abdominal metastases
  • flattening filter-free beams
  • RapidArc
  • volumetric-modulated arc therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{d08009cc6cea4924ba6e014634f3de50,
title = "Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases",
abstract = "Aim: To study clinical outcome for oligometastatic patients (abdominal lymph-node metastases) treated with stereotactic body radiation therapy. Materials and methods: Seventy-one patients were studied retrospectively. Dose prescription was 45 Gy in six fractions. Clinical outcome was assessed with actuarial analysis. Results: The median follow-up was 1.5 years; 45 patients (63.3{\%}) had solitary metastasis, and 26 (36.6{\%}) had multiple lesions. Local control was achieved in 97.5{\%} with a 1-year actuarial rate of 83{\%}. Two-year progression-free survival was 63.1{\%}, and the overall survival was 76.9{\%}. Two patients (3{\%}) developed grade 2 gastro-enteric toxicity. Conclusions: The treatment provided adequate clinical response in the management of oligometastatic cases.",
keywords = "Abdominal metastases, flattening filter-free beams, RapidArc, volumetric-modulated arc therapy",
author = "Ciro Franzese and Luca Cozzi and Davide Franceschini and Giuseppe D'Agostino and Tiziana Comito and {De Rose}, Fiorenza and Pierina Navarria and Pietro Mancosu and Stefano Tomatis and Antonella Fogliata and Marta Scorsetti",
year = "2016",
month = "6",
day = "24",
doi = "10.1080/07357907.2016.1197235",
language = "English",
pages = "1--7",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases

AU - Franzese, Ciro

AU - Cozzi, Luca

AU - Franceschini, Davide

AU - D'Agostino, Giuseppe

AU - Comito, Tiziana

AU - De Rose, Fiorenza

AU - Navarria, Pierina

AU - Mancosu, Pietro

AU - Tomatis, Stefano

AU - Fogliata, Antonella

AU - Scorsetti, Marta

PY - 2016/6/24

Y1 - 2016/6/24

N2 - Aim: To study clinical outcome for oligometastatic patients (abdominal lymph-node metastases) treated with stereotactic body radiation therapy. Materials and methods: Seventy-one patients were studied retrospectively. Dose prescription was 45 Gy in six fractions. Clinical outcome was assessed with actuarial analysis. Results: The median follow-up was 1.5 years; 45 patients (63.3%) had solitary metastasis, and 26 (36.6%) had multiple lesions. Local control was achieved in 97.5% with a 1-year actuarial rate of 83%. Two-year progression-free survival was 63.1%, and the overall survival was 76.9%. Two patients (3%) developed grade 2 gastro-enteric toxicity. Conclusions: The treatment provided adequate clinical response in the management of oligometastatic cases.

AB - Aim: To study clinical outcome for oligometastatic patients (abdominal lymph-node metastases) treated with stereotactic body radiation therapy. Materials and methods: Seventy-one patients were studied retrospectively. Dose prescription was 45 Gy in six fractions. Clinical outcome was assessed with actuarial analysis. Results: The median follow-up was 1.5 years; 45 patients (63.3%) had solitary metastasis, and 26 (36.6%) had multiple lesions. Local control was achieved in 97.5% with a 1-year actuarial rate of 83%. Two-year progression-free survival was 63.1%, and the overall survival was 76.9%. Two patients (3%) developed grade 2 gastro-enteric toxicity. Conclusions: The treatment provided adequate clinical response in the management of oligometastatic cases.

KW - Abdominal metastases

KW - flattening filter-free beams

KW - RapidArc

KW - volumetric-modulated arc therapy

UR - http://www.scopus.com/inward/record.url?scp=84978468763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978468763&partnerID=8YFLogxK

U2 - 10.1080/07357907.2016.1197235

DO - 10.1080/07357907.2016.1197235

M3 - Article

AN - SCOPUS:84978468763

SP - 1

EP - 7

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

ER -